Recently, the United States Food and Drug Administration granted fast-track status to a phase 2 trial of the novel MDM2–p53 inhibitor alrizomadlin (APG-115), which demonstrated preliminary antitumor activity also in uveal melanoma [138]. This evidence concerns the gene TP53 and uveal melanoma.